Aprocitentan

阿普昔腾坦

Report date: 2026/05/14 20:00:28
NME

Base Information

Drug NameAprocitentan
Drug Alias NameAprocitentan - Idorsia PharmaceuticalsTRYVIOJERAYGOJNJ-2820ACT-132577 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEndothelin receptor type B antagonistsEndothelin receptor type A antagonists
TargetsEndothelin receptor type AEndothelin receptor type B
Therapy Area/IndicationsEssential HypertensionHypertensionRenal Insufficiency, Chronic +[4] 
Global Approved IndicationsHypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/03/19
Country/TerritoryCzechiaBelgiumCanada +[23] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesIdorsia Pharmaceuticals LtdActelion Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesIdorsia LtdJanssen Biotech IncIdorsia Pharmaceuticals Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsHypertension
Inactive IndicationsEssential HypertensionRenal Insufficiency, ChronicHepatic Insufficiency

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG